Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| University of Zambia | OTHER |
Not provided
Not provided
Not provided
Not provided
The goal of this clinical trial is to learn if the TwySHE intervention can increase the use of HIV prevention in at-risk female university students aged 18-24 in Zambia. The main question it aims to answer is:
• Can a mhealth peer navigator intervention effectively promote HIV pre-exposure prophylaxis PrEP use among high-risk female students in Zambia?
Researchers will compare the mhealth peer navigator intervention to treatment as usual to see if there are effects on female student's use and continuation of PrEP for HIV prevention.
Participants in the intervention will be paired with a trained peer navigator who will offer education, social support, and help navigating the health systems to access PrEP and other sexual and reproductive health services.
All participants in both arms will complete surveys at baseline, 6 months, and 12 months to evaluate health behaviors.
We are conducting a 1:1 individual-randomized, open-label single-site hybrid type 1 effectiveness-implementation trial to determine the effectiveness the TwySHE intervention in Lusaka, Zambia. We will follow all participants for 12 months with regular data collection. All intervention activities will end at 6 months (primary endpoint window), but we will continue to follow and survey participants in both study arms at 12 months to determine long-term post-intervention effectiveness. PrEP and contraception uptake and persistence will be objectively verified using a study medical visit card filled out and signed by health providers. We will also collect and assess behavioral mechanisms hypothesized to be on the casual pathway, including participant knowledge regarding HIV and unintended pregnancy prevention, health beliefs (perceived risk of HIV or unintended pregnancy), perceived social support to access and adhere to HIV/unintended pregnancy prevention methods, stigma, behavioral intention to use PrEP and contraception, and self-efficacy to use PrEP and contraception. Lastly, we will conduct exit interviews with peer-navigators and a sub-sample of participants to explore the implementation outcomes of the trial.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| TwySHE mhealth peer navigator intervention | Experimental | Trained peer navigators will promote PrEP and contraception uptake/persistence among participants by communicating with them in-person or over mobile devices twice per month for 6 months. The first visit (in-person) is focused on building rapport and a trusting relationship with the participant. During the second visit (in-person) and subsequent sessions (in-person or mobile communication), the peer navigators will focus on encouraging, supporting, and helping build the skills of their participants to address their HIV/SRH needs, provide referrals and linkage to available services, and follow up to ensure participants access those services. Subsequent visits will be conducted as needed, depending on the participant. |
|
| Control | No Intervention | Participants will receive a referral list for local HIV/SRH services and informed of the longitudinal data collection process through 12 months. |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| TwySHE | Behavioral | Interpersonal support from trained peers to access and use PrEP and contraception. |
|
| Measure | Description | Time Frame |
|---|---|---|
| PrEP uptake | Self-reported use of PrEP products verified through health clinic documentation | 6 months |
| Measure | Description | Time Frame |
|---|---|---|
| Contraception uptake | Self-reported use of PrEP products verified through health clinic documentation | 6 months |
| Measure | Description | Time Frame |
|---|---|---|
| PrEP persistence | Self-reported continued use of PrEP if initiated verified through health clinic documentation | 12 months |
| Contraception persistence | Self-reported continued use of PrEP if initiated verified through health clinic documentation |
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Karen M Hampanda, PhD | University of Colorado, Denver | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| University of Zambia | Lusaka | Zambia |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 41781994 | Derived | Hampanda K, Amstutz A, Nayame L, Sehrt M, Hamoonga T, Menon JA, Mumbula I, Mulawa M, Nkole E, Matenga FJ, Mugode M, Mweemba O. TwySHE-an mHealth peer-navigator intervention to increase PrEP and contraceptive use among female university students in Zambia: study protocol of a hybrid effectiveness-implementation randomized controlled trial. Trials. 2026 Mar 5;27(1):296. doi: 10.1186/s13063-026-09545-2. |
Not provided
Not provided
Individual participant data that underlie the results after deidentification
After publication
Researchers who provide a methodologically sound proposal and sign a data use agreement
Not provided
Not provided
| ID | Term |
|---|---|
| D000163 | Acquired Immunodeficiency Syndrome |
| D003268 | Contraception Behavior |
| ID | Term |
|---|---|
| D015658 | HIV Infections |
| D000086982 | Blood-Borne Infections |
| D003141 | Communicable Diseases |
| D007239 | Infections |
Not provided
Not provided
1:1 individual-randomized, open-label single-site hybrid type 1 effectiveness-implementation trial
Not provided
Not provided
Not provided
Not provided
| 12 months |
| D015229 |
| Sexually Transmitted Diseases, Viral |
| D012749 | Sexually Transmitted Diseases |
| D016180 | Lentivirus Infections |
| D012192 | Retroviridae Infections |
| D012327 | RNA Virus Infections |
| D014777 | Virus Diseases |
| D012897 | Slow Virus Diseases |
| D000091662 | Genital Diseases |
| D000091642 | Urogenital Diseases |
| D007153 | Immunologic Deficiency Syndromes |
| D007154 | Immune System Diseases |
| D043762 | Reproductive Behavior |
| D001519 | Behavior |